Overview

A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy

Status:
NOT_YET_RECRUITING

Trial end date:
2029-03-01

Target enrollment:

Participant gender:

Summary

This study is a multicenter, randomized, controlled, open-label, Phase clinical study to evaluate the efficacy, safety, Pharmacokinetics characteristics, Pharmacodynamics effects, and immunogenicity of JMT601 in participants with primary membranous nephropathy. The study has two parts. Part one is dose escalation part, and Part two is dose expansion part.

Phase:

PHASE2

Details

Lead Sponsor:

Shanghai JMT-Bio Inc.

Treatments:

Cyclosporine
Rituximab